Vertex Pharmaceuticals Incorporated (VRTX)の価格はいくらですか

Vertex Pharmaceuticals Incorporated (VRTX)の価格は$451.59です

Vertex Pharmaceuticals Incorporated (VRTX)の時価総額は何ですか

Vertex Pharmaceuticals Incorporated (VRTX)の時価総額は$114.70Bです

Vertex Pharmaceuticals Incorporated（VRTX）PBR（株価純資産倍率）

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

年	P/B比率	変化
2026 (TTM)	6.38	1.02%
2024	6.32	5.95%
2023	5.96	12.20%
2022	5.32	-5.13%
2021	5.60	-20.74%
2020	7.07	-23.47%
2019	9.24	-2.78%
2018	9.50	-48.32%
2017	18.38	18.49%
2016	15.52	-51.87%
2015	32.24	24.19%
2014	25.96	110.80%
2013	12.32	38.57%
2012	8.89	2.78%
2011	8.65	-37.92%
2010	13.93	105.70%
2009	6.77	-62.12%
2008	17.88	61.85%
2007	11.04	31.89%
2006	8.37	-18.89%
2005	10.32	-55.94%
2004	23.43	467.01%
2003	4.13	30.31%
2002	3.17	-17.67%
2001	3.85	-59.09%
2000	9.41	0.00%

年

P/B比率

変化

2026 (TTM)

6.38

1.02%

2024

6.32

5.95%

2023

5.96

12.20%

2022

5.32

-5.13%

2021

5.60

-20.74%

2020

7.07

-23.47%

2019

9.24

-2.78%

2018

9.50

-48.32%

2017

18.38

18.49%

2016

15.52

-51.87%

2015

32.24

24.19%

2014

25.96

110.80%

2013

12.32

38.57%

2012

8.89

2.78%

2011

8.65

-37.92%

2010

13.93

105.70%

2009

6.77

-62.12%

2008

17.88

61.85%

2007

11.04

31.89%

2006

8.37

-18.89%

2005

10.32

-55.94%

2004

23.43

467.01%

2003

4.13

30.31%

2002

3.17

-17.67%

2001

3.85

-59.09%

2000

9.41

0.00%

企業	P/B比率	P/B比率の差	国
Novo Nordisk A/S NVO.US	5.6573	-11.39%	DK
Regeneron Pharmaceuticals, Inc. REGN.US	2.4551	-61.54%	US
UCB SA UCB.BR	4.364	-31.64%	BE
CSL Limited CSL.AX	2.5504	-60.05%	AU
Argenx SE ARGX.US	5.9034	-7.53%	NL

企業

P/B比率

P/B比率の差

国